AntagomiR-based therapy for T2DM: MiRNA-4500 promotes glucose intolerance and insulin resistance via down regulation of its target gene, 10/February/2015, 23.16

Natural product-based therapy for Cancer: Agaricus blazei Murill (AbM) inhibits glycolysis and cancer progression via down regulation of PDK1, 10/February/2015, 23.04
February 10, 2015
Molecular therapy for Inflammatory Bowel disease (IBD): p63 preserves the functions of Beclin 1 and ATG5 and decreases tissue injury in inflammatory bowel disease (IBD) via down regulation of its target gene, 10/February/2015, 23.22
February 10, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, AntagomiR-based therapy for T2DM: MiRNA-4500 promotes glucose intolerance and insulin resistance via down regulation of its target gene, 10/February/2015, 23.16, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that MiRNA-4500, by suppressing the expression of its target gene, it may promote glucose intolerance and insulin resistance.  Thus, pharmacological formulations encompassing “miRNA-4500 inhibitors  may be used to inhibit glucose intolerance and insulin resistance and promote insulin sensitivity.

Amount: $ 300*

Undisclosed information: How miRNA-4500 inhibits glucose intolerance and insulin resistance

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.